Novo Nordisk A/S
(NYSE : NVO)

( )
NVO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -2.46%144.460.7%$923.06m
PFEPfizer Inc. -0.37%37.810.9%$790.83m
BMYBristol-Myers Squibb Co. -0.75%60.781.0%$657.39m
MRKMerck & Co., Inc. -1.48%78.650.7%$623.31m
ABBVAbbVie, Inc. -2.26%84.321.9%$591.87m
LLYEli Lilly & Co. -2.37%142.661.1%$506.47m
AZNAstraZeneca Plc -1.11%52.441.2%$199.31m
NVSNovartis AG -0.49%85.770.2%$145.37m
GSKGlaxoSmithKline Plc -1.12%36.160.2%$133.98m
NVONovo Nordisk A/S -0.34%70.780.1%$69.97m
RGENRepligen Corp. -1.18%168.757.1%$62.44m
PRAXPraxis Precision Medicines, Inc. -1.98%27.250.0%$62.40m
RPRXRoyalty Pharma Plc -3.68%40.270.2%$57.90m
SNYSanofi -0.26%50.140.2%$50.33m
AMAGAMAG Pharmaceuticals, Inc. 0.07%13.6422.1%$45.46m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.